Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.

"We faced some interesting challenges to make this website genuinely helpful to the wide range of people who might visit it," said Gilman Wong, Chief Executive Officer of Sirtex Medical Limited.

"For example, administering SIR-Spheres microspheres to patients requires the skills of a team of doctors and nurses from medical oncology, hepatology, gastroenterology, liver surgery, interventional radiology, nuclear medicine and radiation oncology.  Each discipline is critical to meeting the needs of a patient with liver tumours, but all have different perspectives and informational needs relative to SIR-Spheres microspheres," he explained.

"The same holds true of patients.  A patient with primary liver cancer, or hepatocellular carcinoma (HCC), has a disease that is quite different from a patient with metastatic colorectal cancer (mCRC), who may have already undergone extensive surgical, radiation and chemotherapy treatments before considering SIR-Spheres microspheres," Mr. Wong stated.

http://www.sirtex.com has specialised content for all these diverse audiences, as well as for patient groups, through to those interested in investing in this rapidly emerging technology.  Content is also regionalised for Europe, Asia-Pacific, Australia and the Americas.

"In addition to making our website useful to a cross-section of people that is quite extensive for a therapy that is itself highly specific, our other big challenge was to stay current with a rapidly growing research data base, including a number of new studies that may lead to the use of SIR-Spheres microspheres earlier and in a larger population of patients with liver cancers," Mr. Wong added.